<DOC>
	<DOC>NCT02754141</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, pharmacodynamics, anti-tumor activity, and pharmacokinetics of BMS-986179 when combined with nivolumab in patients with advanced cancer.</brief_summary>
	<brief_title>A Study of BMS-986179 Administered in Combination With Nivolumab in Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Men and women at least 18 years of age Advanced solid tumors Eastern Cooperative Oncology Group (ECOG) 01 Acceptable lab testing results Allow biopsies Central nervous system (CNS) tumors Uncontrolled or significant cardiovascular diseases Active or known autoimmune disease Organ transplant Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>